- Home
- YSXT vs ANL Comparison
YSXT vs ANL Comparison
Compare YSXT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | YSXT | ANL |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | China | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 350.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | YSXT | ANL |
|---|---|---|
| Price | $1.38 | $8.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 348.5K | 214.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.88 |
| 52 Week High | $9.90 | $12.09 |
Technical Indicators
Market Signals| Indicator | YSXT | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 61.67 | 55.38 |
| Support Level | $1.08 | $1.37 |
| Resistance Level | $1.47 | $10.15 |
| Average True Range (ATR) | 0.13 | 0.97 |
| MACD | 0.03 | -0.27 |
| Stochastic Oscillator | 58.33 | 56.12 |
Price Performance
Historical ComparisonAbout YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.